Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAMeLot-1 phase 2 bleximenib monotherapy in relapsed/refractory acute myeloid leukemia with KMT2A or NPM1 alterations
MOH_2024-10-10_013681Phase 2Active, not recruiting
- Sponsor
- Janssen-Cilag
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bleximenib in acute myeloid leukemia (AML) and Acute Leukaemia, sponsored by Janssen-Cilag. Started Oct 2024; status: active, not recruiting.
02
Drugs
bleximenib
03
Conditions
acute myeloid leukemia (AML)Acute Leukaemia
Beyond the preview
Go deeper on MOH_2024-10-10_013681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-10-10_013681.